Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 51, 6190-6193, November 15, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Templeton, N. S.
Right arrow Articles by Stetler-Stevenson, W. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Templeton, N. S.
Right arrow Articles by Stetler-Stevenson, W. G.

Identification of a Basal Promoter for the Human Mr 72,000 Type IV Collagenase Gene and Enhanced Expression in a Highly Metastatic Cell Line

Nancy Smyth Templeton1 and William G. Stetler-Stevenson

Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, Maryland 20892

A basal promoter for the Mr 72,000 type IV collagenase gene was specifically defined by chloramphenicol acetyltransferase assays of a nested set of 5' upstream fragments containing the promoter region. This core promoter is TACATCT and is a noncanonical TATA box that fits the TATA consensus sequence. This sequence begins 26 base pairs in the upstream direction from the start site of transcription for the type IV collagenase gene. This basal promoter is active in the highly metastatic A2058 melanoma cell line. A putative enhancer was found between nucleotides -223 to -422 that produces a 7-fold increase in transcriptional activity in the A2058 melanoma cell line. The region immediately 5' of the basal promoter, upstream to position -422, contains a silencer and represses transcriptional activity in the nonmetastatic HT144 melanoma cell line. The results of this study are consistent with previous data that found high expression of Mr 72,000 type IV collagenase mRNA and enzymatic activity in the A2058 cell line, whereas low mRNA expression and type IV collagenase activity were found in the HT144 cell line.

1 To whom requests for reprints should be addressed, at Molecular Hematology Branch, National Heart, Lung, and Blood Institute, Building 10, Room 7D18, Bethesda, MD 20892.

Received 7/30/91. Accepted 9/25/91.




This article has been cited by other articles:


Home page
IOVSHome page
R. N. Weinreb and J. D. Lindsey
Metalloproteinase Gene Transcription in Human Ciliary Muscle Cells with Latanoprost
Invest. Ophthalmol. Vis. Sci., March 1, 2002; 43(3): 716 - 722.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
K. L. SHARPE-TIMMS and K. E. COX
Paracrine Regulation of Matrix Metalloproteinase Expression in Endometriosis
Ann. N.Y. Acad. Sci., March 1, 2002; 955(1): 147 - 156.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
J. A. Rada, C. A. Perry, M. L. Slover, and V. R. Achen
Gelatinase A and TIMP-2 Expression in the Fibrous Sclera of Myopic and Recovering Chick Eyes
Invest. Ophthalmol. Vis. Sci., December 1, 1999; 40(13): 3091 - 3099.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1991 by the American Association for Cancer Research.